Leerink Partnrs Analysts Raise Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for BioMarin Pharmaceutical in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of $0.94 per share for the quarter, up from their previous estimate of $0.81. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Other equities analysts have also recently issued reports about the company. William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Bank of America boosted their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup boosted their target price on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a “neutral” rating in a research report on Thursday. Evercore ISI cut their price objective on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, Scotiabank upped their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.81.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $68.25 on Monday. The stock has a market cap of $13.01 billion, a PE ratio of 31.02, a price-to-earnings-growth ratio of 0.61 and a beta of 0.28. BioMarin Pharmaceutical has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The stock has a fifty day moving average of $64.88 and a 200-day moving average of $70.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Institutional Trading of BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mackenzie Financial Corp grew its stake in shares of BioMarin Pharmaceutical by 203.4% in the 4th quarter. Mackenzie Financial Corp now owns 220,661 shares of the biotechnology company’s stock worth $14,504,000 after buying an additional 147,927 shares during the last quarter. Forum Financial Management LP purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $298,000. Toronto Dominion Bank grew its stake in shares of BioMarin Pharmaceutical by 3.8% in the 4th quarter. Toronto Dominion Bank now owns 24,862 shares of the biotechnology company’s stock worth $1,634,000 after buying an additional 920 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in BioMarin Pharmaceutical during the 4th quarter valued at $263,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in BioMarin Pharmaceutical by 19.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company’s stock valued at $69,351,000 after purchasing an additional 174,634 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.